Diagnostic Access: Clinical Diagnosis Without Specialized Testing

In high-income countries, ME/CFS is diagnosed by exclusion after ruling out anemia, hypothyroidism, autoimmune disease, and other fatigue-causing conditions. In LMICs, access to even basic laboratory testing is inconsistent. This creates a paradox: the same diagnostic criteria are harder to apply, not because the disease is rarer, but because the exclusionary workup is less available.

Achievement: Clinical Diagnosis Without Exclusionary Testing Is the Global Default

ME/CFS diagnostic criteria (IOM 2015, CCC 2003) require exclusion of alternative diagnoses. In settings without reliable TSH, CBC, ferritin, CRP, or ANA testing, that exclusion is incomplete — the diagnostic algorithm simply cannot be executed as written. Podell et al. document the practical requirements for ME/CFS disability recognition, including the laboratory exclusion workup, and note that ICD coding (G93.3 in ICD-10, 8E49 in ICD-11) exists regardless of local testing capacity (Podell2020documentingDisability?). The ICD code is globally available. The diagnostic pathway that justifies assigning it is not.

The Bangladesh ME/CFS RCT protocol represents the first registered clinical trial from a South Asian LMIC setting (Sarker2024bangladeshRCTprotocol?). The protocol applies Fukuda criteria — but the infrastructure required to rule out alternative diagnoses in rural Bangladesh differs substantially from what is available in Massachusetts. The trial’s existence is a milestone. Its reliance on Fukuda criteria (rather than IOM 2015) reflects a pragmatic reality: the Fukuda criteria are simpler to apply without specialized testing and remain the most commonly used criteria in LMIC research settings.

(Certainty: 0.50 — the diagnostic-access constraint is structural and not dependent on empirical data. The Bangladesh trial protocol is published but results are pending.)

Consequence: The global diagnostic gap is not about the absence of diagnostic criteria — it is about the absence of the diagnostic infrastructure those criteria assume. For a patient in a setting without reliable laboratory testing, an ME/CFS diagnosis cannot be made with the same certainty as in a high-income country. This does not mean the patient does not have ME/CFS. It means the criteria were not designed for their setting. Severity applicability: all — the diagnostic gap affects all severity levels, though mild cases are most likely to be missed entirely.

Falsifiable prediction: If a simplified diagnostic protocol (history + physical exam + point-of-care hemoglobin only, omitting TSH/ferritin/CRP/ANA) achieves sensitivity ≥0.90 vs. a full-exclusion diagnostic workup in the same primary care population, the diagnostic-access constraint is surmountable by protocol adaptation. If sensitivity falls below 0.70, the diagnostic gap is structural and cannot be bridged without laboratory infrastructure.